A tablet containing brexpiprazole

The use of sodium stearyl fumarate in brexpiprazole tablets with precise particle sizes and excipients addresses solubility issues, resulting in stable and uniformly dissolving tablets with improved bioavailability.

TR202318022BActive Publication Date: 2026-10-21SANOVEL ILAC SANAYI & TICARET ANONIM SIRKETI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TR202318022
Authority / Receiving Office
TR · TR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-22
Publication Date
2026-10-21
Estimated Expiration
2043-12-22

AI Technical Summary

Technical Problem

Brexpiprazole's low water solubility poses a challenge in formulation, leading to stability issues and uneven dissolution profiles, which affect its effectiveness and ease of production.

Method used

A tablet formulation using brexpiprazole with sodium stearyl fumarate as a lubricant, combined with specific particle sizes and excipients, ensures uniform content, high stability, and improved dissolution properties.

Benefits of technology

The formulation achieves homogeneous dissolution profiles, enhanced stability, and better bioavailability, making it suitable for cost-effective and efficient production.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a tablet containing brexpiprazole or one of its salts and at least one pharmaceutically acceptable excipient, where sodium stearyl fumarate is present as a lubricant. The present invention also relates to a simple, rapid, cost-effective, time-saving and industrially feasible process.
Need to check novelty before this filing date? Find Prior Art

Description

1 TARIFF A tablet containing brexpiprazole Field of Invention The present invention describes brexspiprazole or one of its salts and at least one pharmaceutically acceptable solution. This relates to a tablet containing an excipient, in which sodium stearyl fumarate is present as a lubricant. 5 Furthermore, the present invention is simple, fast, cost-effective, time-saving, and industrially viable. It is also related to the process. Background of the Invention Brexpiprazole is a partial agonist of the serotonin 5-HT1A receptor and dopamine D2 and D3 receptors. It functions. Brexpiprazole is used in 10 cases of schizophrenia, depression, and other central nervous system disorders. in the treatment of and management of behavioral and psychological symptoms or mental health issues associated with neurodegenerative disease. Use described in the prophylaxis and / or treatment of impulsive symptoms associated with the disease. It has been done. Brexpiprazole is a compound represented by the following Formula I and its chemical name is 7-[4-[4-(1-benzothiophene- 4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one. 15 Formula I Brexpiprazole is used orally for the treatment of schizophrenia and as an antidepressant in major depressive disorder. It is an antidepressant and antipsychotic medication marketed under the brand name Rexulti® as an adjunct therapy. REXULTI tablets are intended for oral administration and are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg doses. It is available in their respective strengths. The product was developed in the USA in 2015 for the indications mentioned above. It has been approved and is currently used to treat agitation associated with Alzheimer's disease and PTSD (post-traumatic stress disorder). It is in phase III trials for the treatment of stress disorder. Brexpiprazole has poor water solubility. Its low solubility is the main limitation of the drug. Therefore, solubility is important in a formulation containing brexpiprazole. 25 Patent application number WO2019121849 describes a) brexpiprazole as the active ingredient and b) at least 5% by weight of the same substance. A pharmaceutical in tablet form containing (by weight %) pregelatinized starch (PGS). 2 It relates to composition. The invention involves the dry granulation of a mixture of components to produce granules. and relates to tablet preparation methods, which involve compressing granules into a tablet shape. Patent application EP3545950A1 describes a pharmaceutical product containing a granulate with brexpiprazole. This relates to the composition, where the granule is a carrier, a brexpiprazole in a solvent system. It is obtained by wet granulation using a granulation liquid that is a solution. 5 In previous techniques, the low solubility of brexspiprazole was approached in various ways. However, the dissolution... We found that the efforts to improve its profile could cause some stability problems. As clearly seen from previous techniques and literature, various pharmaceuticals containing brexpiprazole Compositions have been reported. Brexpiprazole or a pharmaceutically acceptable alternative. 10 containing salt, having high stability, uniform content, improved compressibility and fluidity. for oral dosage formulations that are safe, effective and easy to produce using manufacturing methods There is a current and ongoing need. The desired tablet contains brexpiprazole or one of its salts and sodium stearyl fumarate as a lubricant. We found that it positively affected high stability. The resulting tablets also had the desired effect. It has a homogeneous dissolution profile. The tablet is a standard 15-pack, a simple and cost-effective method. It was developed using various techniques. Detailed Description of the Invention The main objective of the present invention is to produce a tablet containing brexpiprazole with uniform content and high stability. to provide. Another objective of the present invention is to produce a 20-dose solution containing brexpiprazole with the desired level of dissolution profile. The goal is to provide tablets. Another aim of the present invention is to provide a simple and rapid method for preparing a tablet containing brexpiprazole. The goal is to provide a cost-effective, time-saving, and industrially viable process. As is known, the use of lubricants ensures excellent adhesion of powders throughout the process involving brexpiprazole. It ensures fluidity. In the present invention, the use of sodium stearyl fumarate also ensures a good 25% fluidity of the tablet. We also saw that it provided stability. When a tablet containing brexpiprazole is formulated with sodium stearyl fumarate, it exhibits high stability. We observed that it positively affected powder homogenization. The resulting tablets had the desired dissolution. 3 It has a profile. The powder is more homogeneous. The tablets obtained from the more homogeneous powder have a different composition. Its uniformity is more ideal. Therefore, it provides better bioavailability. According to a regulation of the present invention, one tablet contains brexpiprazole or a salt thereof and a pharmaceutical It contains at least one acceptable excipient, in which case sodium stearyl is used as a lubricant. Fumarate is present. 5 According to this arrangement of the present invention, the amount of lubricant in the tablet is equal to the weight of the total composition. It is between 0.1% and 3.0%. According to a regulation of the present invention, the amount of brexpiprazole or one of its salts, in total The percentage of the composition is between 0.1% and 10.0% by weight. The following 10 particle sizes of brexspiprazole or its salt are crucial for formulation. We found that it particularly has a positive effect on dissolution properties. The resulting tablets are as desired. It has a dissolution profile. As used here, 'particle size' refers to the laser diffraction method (e.g., Malvern Mastersizer 2000). cumulative volume size tested by any traditionally accepted method (such as analysis). It means distribution. The term d (0.9) expresses the dimension in which 90% of the particles are finer by volume. 15 does. In one arrangement of the invention, brexpiprazole or one of its salts, with a particle size between 1 µm and 35 µm, preferably 3 It has a particle size d (0.9) between µm and 27 µm. According to this arrangement of the present invention, tablets, fillers, binders, dispersants, lubricants or at least one pharmaceutically acceptable 20 selected from a group consisting of these or mixtures thereof. It contains excipients. Suitable fillers include lactose monohydrate, microcrystalline cellulose, mannitol, and pre-gelatinized oil. starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dihydrate, Neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, polydextrose, polymethacrylates, 25 sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, polysorbate 80, xylitol or It is selected from the group that contains mixtures of these. According to this arrangement of the present invention, the filler consists of lactose monohydrate and microcrystalline cellulose. These are anhydrous lactose or mixtures thereof. 4 According to this arrangement of the present invention, the filler materials are lactose monohydrate and microcrystalline cellulose. According to this arrangement of the present invention, the filler material is anhydrous lactose and microcrystalline cellulose. According to this arrangement of the present invention, the amount of filler in the tablet is a percentage of the total composition. It is 80.0% to 95.0% by weight. Preferably, it is 86.0% to 92.0% by weight of the total composition. Suitable binders include polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, 5 carbomers, cellulose acetate phthalate, chitosan, starch, corn starch, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, Poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, sucrose, polyoxyethylene-alkyl Ethers are selected from the group consisting of pullulans or mixtures thereof. 10 According to this arrangement of the present invention, the binder shall be polyvinylpyrrolidone or hydroxypropyl cellulose or They are mixtures of these. According to this arrangement of the present invention, the amount of binder in the tablet is equal to the weight of the total composition. It ranges from 1.0% to 10.0%. Preferably, it is 2.0% to 6.0% by weight of the total composition. Suitable dispersants include sodium starch glycolate, crospovidon, and cross-linked carboxymethyl cellulose 15. (croscarmellose sodium), low-substitution hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, Guar gum, sodium alginate, alginic acid, magnesium aluminum silica, poloxamer, sodium glycine It is selected from the group consisting of carbonates or mixtures thereof. According to this arrangement of the present invention, the dispersant is crospovidon. According to this arrangement of the present invention, the amount of dispersant in the tablet is 20% of the total composition. 2.0% to 10.0% by weight, preferably 2.5% to 6.0% by weight, and even more preferably 2.8% to 5.5% by weight. The dispersion ratio ensures the desired dissolution profile and high stability in the tablet while also It also ensured homogeneity. According to this arrangement of the present invention, the tablet in question is used as a core tablet and further It is then coated with a film to obtain a film-coated tablet form. The film coating is HPMC 25. or PVA-based. According to this arrangement of the present invention, the tablet in question is used as a mini-tablet and then... The tablets are packed into capsules. 0.25 mg mini-tablets are placed in different capsules. Easy access is provided to every dose of the brexpiprazole product. According to this arrangement of the present invention, the tablet includes the following: ▪ D90 refers to brexpiprazole or a derivative thereof, with a particle size smaller than approximately 35 microns. salt, ▪ Hydroxypropyl cellulose or polyvinylpyrrolidone ▪ Crospovidon 5 ▪ Sodium stearyl fumarate According to this arrangement of the present invention, the tablet includes the following: ▪ D90 refers to brexspiprazole or a derivative thereof, with a particle size smaller than approximately 35 microns. salt, ▪ Lactose monohydrate or anhydrous lactose 10 ▪ Microcrystalline cellulose ▪ Crospovidon ▪ Sodium stearyl fumarate According to this arrangement of the present invention, the tablet can be printed using direct printing, a simple and cost-effective method. or prepared by compression method. These processes are solvent-free, which means the active ingredient and therefore 15 It helps to stabilize the tablet's stability. According to this arrangement of the present invention, a tablet containing brexpiprazole or one of its salts The process for its preparation includes the following steps: a) Mixing the filler materials used, b) Brexpiprazole mixed with at least one binder and at least one dispersant, 20 c) Mixing the mixture in step (a) and the mixture in step (b) by geometric dilution. d) Adding and mixing the mixture, e) Adding sodium stearyl fumarate and then mixing, f) Pressing the total mixture into tablet form. Example 1: Tablet 6 Components of the Formulation by weight % CORE TABLET components inside - by weight % CORE TABLET components inside - by weight % MINI TABLET inside components - by weight % Brexpiprazole 0.1 -10.0 1.04 3.33 1.00 Lactose (Supertab 24 AN) or lactose monohydrate 40.0 – 64.0 45.83 59.67 62.00 Microcrystalline cellulose 25.0 – 50.0 45.83 30.00 30.00 Polyvinylpyrrolidone 1.0 -10.0 3.13 3.00 3.00 Crospovidone 2.0 -10.0 3.13 3.00 3.00 Sodium stearyl fumarate 0.1 - 3.0 1.04 1.00 1.00 TOTAL 100 100 100 100 A process for Example 1; a) Mixing lactose monohydrate or anhydrous lactose with microcrystalline cellulose, b) Mixing brexpiprazole, polyvinylpyrrolidone, and crospovidon, c) Mixing the mixture in step (a) and the mixture in step (b) by geometric dilution. d) Sifting the mixture to a 0.9 mm sieve and then mixing, 5 e) Adding sodium stearyl fumarate and then mixing, f) Pressing the total mixture into tablet form. Ideally, tablets are available in mini-tablet form, and these mini-tablets are packed into capsules. Ideally, the tablet is coated with a film to obtain a film-coated tablet. A process for Example 2; 10 a) Mixing lactose monohydrate or anhydrous lactose with microcrystalline cellulose, b) Half of brexpiprazole, polyvinylpyrrolidone, crospovidon, and sodium stearyl fumarate mixing, c) Mixing the mixture in step (a) and the mixture in step (b) by geometric dilution. d) Sifting the mixture to a 0.9 mm sieve and then mixing, 15 e) Compressing the mixture using a compaction machine. f) Adding the remaining sodium stearyl fumarate and then mixing, g) Pressing the total mixture into tablet form. Ideally, tablets are available in mini-tablet form, and these mini-tablets are packed into capsules. Preferably, to obtain a film-coated tablet, the tablet is coated with a film coating. 20 7 Example 2: Tablet Total Components formulation by weight % CORE TABLET components inside - by weight % MINI TABLET components inside - by weight % Brexpiprazole 0.1 -10.0 3.33 1.00 Lactose (Supertab 24 AN) 40.0 – 64.0 59.67 62.00 Microcrystalline cellulose 25.0 – 50.0 30.00 30.00 Hydroxypropyl Cellulose 1.0 -10.0 3.00 3.00 Crospovidone 2.0 -10.0 3.00 3.00 Sodium stearyl fumarate 0.1 - 3.0 1.00 1.00 TOTAL 100 100 100 A process for Example 2; a) Mixing lactose monohydrate or anhydrous lactose with microcrystalline cellulose, b) Mixing brexpiprazole, HPC and crospovidon, c) Mixing the mixture in step (a) with the mixture in step (b) by geometric dilution, d) Sifting the mixture to a 0.9 mm sieve and then mixing it. e) Adding sodium stearyl fumarate and then mixing, f) Pressing the total mixture into tablet form. Ideally, tablets are available in mini-tablet form, and these mini-tablets are packed into capsules. Ideally, the tablet is coated with a film to obtain a film-coated tablet. 10

Claims

1 REQUESTS 1) Brexpiprazole or one of its salts, with at least one binding agent and pharmaceutically acceptable It is a tablet containing at least one excipient, characterized by sodium stearyl fumarate as a lubricant. The presence of brexpiprazole or one of its salts, a particle d (0.9) between 1 µm and 35 µm. It has a certain size and the binders are polyvinylpyrrolidone, carboxymethylcellulose sodium, sugars, agar, alginates, carbomers, cellulose acetate phthalate, chitosan, starch, corn starch, dextrose, ethylcellulose, glyceryl behenate, hydrogenated vegetable oil type I, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, sucrose, polyoxyethylene-alkyl ethers, pullulan or selection from a group consisting of mixtures of these. 2) According to claim 1, it is a tablet containing brexpiprazole or one of its salts, in a concentration of 3 µm to 27 µm. It has a particle size d (0.9) between them. 3) According to Claim 1, it is a tablet, and its characteristic feature is that the tablet contains no fillers, dispersants, lubricants or at least one pharmaceutically acceptable substance selected from a group of mixtures thereof It contains excipients. 4) According to claim 3, it is a tablet, characterized by its filler materials: lactose monohydrate, microcrystalline. cellulose, mannitol, pre-gelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dihydrate, neutral pellets, calcium sulfate, cellulose, ethylcellulose, fructose, glyceryl palmitostearate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, polysorbate 80, xylitol or any of these. It is the selection from the group that includes the mixtures. 5) According to claim 3, it is a tablet, characterized by its filler material being lactose monohydrate, microcrystalline cellulose, It is anhydrous lactose or a mixture thereof. 6) Tablet according to claim 1, characterized by the binder being polyvinylpyrrolidone or hydroxypropyl cellulose. or mixtures thereof. 7) Tablet according to claim 3, containing dispersants, sodium starch glycolate, crospovidon, cross-linking agents. bound carboxymethyl cellulose (croscarmellose sodium), low-substitution hydroxypropyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, sodium alginate, alginic acid, magnesium 2 aluminum silica, poloxamer, sodium glycine carbonate, or mixtures thereof. It is the selection from the group. 8) According to claim 3, it is a tablet, characterized by the fact that the dispenser is crospovidon. 9) According to claim 8, it is a tablet, and its characteristic feature is that the amount of dispersant inside the tablet is between 2.0% and 10.0% by weight. Ideally, it should be between 2.5% and 6.0% by weight. 10) According to Claim 1, it is a tablet, and its characteristic is that the tablet in question is used as a core tablet. and then it is coated with a film to obtain a film-coated tablet form. 11) According to Claim 1, it is a tablet, and its characteristic is that the tablet in question can be used in the form of mini-tablets and then it is filled into a capsule. 12) A tablet according to claim 1 or 3, and its characteristic is that the tablet includes the following: ▪ D90 refers to brexiprazole or one of its salts, with a particle size between 1 µm and 35 µm. ▪ Hydroxypropyl cellulose or polyvinylpyrrolidone ▪ Crospovidon ▪ Sodium stearyl fumarate 13) A tablet according to claim 1 or 3, and its characteristic is that the tablet includes the following: ▪ D90 is brexpiprazole or one of its salts, with a particle size between 1 µm and 35 µm. ▪ Lactose monohydrate or anhydrous lactose ▪ Microcrystalline cellulose ▪ Crospovidon ▪ Sodium stearyl fumarate 14) According to any of the previous requirements, it is a tablet, and its characteristic feature is that the tablet in question is a mini tablet. It is used in its raw form and then filled into a capsule.